Correction to: The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies (Archives of Virology, (2014), 159, 3, (527-534), 10.1007/s00705-013-1862-9);The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies

Archives of Virology

Volumn 159, Issue 3, 2014, Pages 527-534

  Hoffmann, Thomas Walter ^a,b   Delfosse, Fabien ^b   Helle, François ^a   François, Catherine ^a,b   Duverlie, Gilles ^a,b   Castelain, Sandrine ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; LIVER CELL; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY; VIRUS CULTURE; VIRUS REPLICATION;

CELL LINE, TUMOR; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84896817419     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-018-4044-y     Document Type: Erratum

References (34)

1. Murray CL, Rice CM (2011) Turning hepatitis C into a real virus. Annu Rev Microbiol 65: 307-327.
2. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
3. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589-595.
4. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL (2012) Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18: 281-285.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
7. Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K (2011) Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 54: 764-771.
8. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
9. Hoffmann TW, Duverlie G, Bengrine A (2012) MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy. Virol J 9: 109.
10. Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD (2012) Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 69: 2621-2633.
11. Bensadoun P, Rodriguez C, Soulier A, Higgs M, Chevaliez S, Pawlotsky JM (2011) Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable? Hepatology 54: 748.
12. Ehrhardt M, Leidinger P, Keller A, Baumert T, Diez J, Meese E, Meyerhans A (2011) Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology 54: 1112-1113.
13. Akazawa D, Date T, Morikawa K, Murayama A, Omi N, Takahashi H, Nakamura N, Ishii K, Suzuki T, Mizokami M, Mochizuki H, Wakita T (2008) Characterization of infectious hepatitis C virus from liver-derived cell lines. Biochem Biophys Res Commun 377: 747-751.
14. Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642.
15. Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernandez A, Aldabe R, Lopez-Cabrera M, Majano PL (2009) The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 83: 8012-8020.
16. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, Wakita T, Liang TJ (2007) Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 81: 4405-4411.
17. Sainz B Jr, Barretto N, Yu X, Corcoran P, Uprichard SL (2012) Permissiveness of human hepatoma cell lines for HCV infection. Virol J 9: 30.
18. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA (2004) CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78: 1448-1455.
19. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, Matsuura Y (2012) Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 86: 1382-1393.
20. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ (2011) HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 85: 12087-12092.
21. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294-9299.
22. Blight KJ, McKeating JA, Rice CM (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014.
23. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
24. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69: 5761-5767.
25. Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K, Matsuura Y (2012) Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol 86: 7918-7933.
26. Thibault PA, Huys A, Dhillon P, Wilson JA (2013) MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. Virology 436: 179-190.
27. Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, Morel V, Herpe YE, Bengrine A, Belouzard S, Wychowski C, Dubuisson J, Francois C, Regimbeau JM, Castelain S, Duverlie G (2013) Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One 8: e70809.
28. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T (2007) CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 81: 5036-5045.
29. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972-1974.
30. Sainz B Jr, Barretto N, Uprichard SL (2009) Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. PLoS One 4: e6561.
31. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K (2011) IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 54: 1094-1101.
32. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Kamatani N, Chayama K (2011) Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 83: 1597-1607.
33. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N (2012) Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55: 20-29.
34. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.